Chiara Lazzari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chiara Lazzari has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Mariacarmela Santarpia
Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy
2 shared publicationsAlessandra Bulotta
Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy
1 shared publication- Angelo Delmonte
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
1 shared publication Aurora Mirabile
Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy
1 shared publicationChiara Catania
European Institute of Oncology, Division of Thoracic Oncology, Italy
1 shared publicationCristina Noberasco
European Institute of Oncology, Division of Thoracic Oncology, Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 10, 1-12
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported.
- 1 January 2018
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 10, 1-12
Open AccessCombination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported.
- 1 March 2014
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 89 (3) , 358-365
Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options
- 1 March 2014
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 89 (3) , 358-365
Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options